Mohemmed Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohemmed Khan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Brett A. Miles
Northwell Health System
7 shared publications - Alberto Pereira
Instituto Português de Oncologia de Lisboa, 1099-023 Lisbon, Portugal
1 shared publication - Alfred Marc Iloreta
Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Medical Center, New York, NY
1 shared publication - Ali Modabber
Department of Oral and Maxillofacial Surgery University Hospital RWTH Aachen Aachen Germany
1 shared publication Ameya A. Jategaonkar
Barrow Neurological Institute
1 shared publication- Andreas Naros
Department of Oral and Maxillofacial Surgery, University Hospital Tübingen, 72076 Tübingen, Germany
1 shared publication
Latest Publications
- Open Access
- 23 March 2026
- Published by MDPI AG in Craniomaxillofacial Trauma & Reconstruction
- Vol. 19 (1) , 17
A Prospective, International, Multicentre Registry of Patients Undergoing Segmental Mandibular Defect Reconstruction After Mandibular Resection for Tumours and Drug-Induced Osteonecrosis: A Study Protocol
Segmental mandibular resection may be indicated as a treatment in, for example, advanced stages of oral squamous cell carcinoma (OSCC). Osseous reconstruction of these defects is a fundamental part of static and dynamic masticatory rehabilitation, particularly when dental implants are required. The Segmental Mandibular Defect Reconstruction (SMDR) Registry aims to generate real-world evidence on SMDR through an international, prospective, multicentre case series designed as a registry. While OSCC is a common indication for segmental mandibular resection, the SMDR Registry also aims to capture outcomes for rarer mandibular conditions and the increasing number of collateral damage cases resulting from systemic medication therapies (antiresorptive drugs, immunotherapeutics) or irradiation, which may likewise lead to medication-related osteonecrosis of the mandible (MRONJ) or osteo(radio)necrosis with tumour-like segmental resection of the mandible, highlighting the value of an international database for these less frequent pathologies. Primary objectives are to describe the patient population and current treatment modalities, describe the outcomes and adverse events (AEs) for different treatment modalities, and identify potential predictors for successful autologous reconstruction of SMDs. Approximately 300 patients with a mandibular lesion resulting from bisphosphonate- and immunomodulatory drug-induced osteonecrosis of the mandible, ameloblastoma or osteosarcoma of the mandible, oral metastases related mandibular lesions indicated for segmental resection, or OSCC undergoing SMDR or intending to undergo one- or two-stage reconstruction will be prospectively recruited over a 36-month period. Baseline information, treatment details, and outcome measures will be documented. All treatments will be per the usual practice at participating sites. Outcome measures include clinical, patient-reported, and radiological outcomes; AEs related to the condition and/or treatment with a possible influence on the outcome will be recorded.
- 23 March 2026
- Published by MDPI AG in Craniomaxillofacial Trauma & Reconstruction
- Vol. 19 (1) , 17
Open AccessA Prospective, International, Multicentre Registry of Patients Undergoing Segmental Mandibular Defect Reconstruction After Mandibular Resection for Tumours and Drug-Induced Osteonecrosis: A Study Protocol
Segmental mandibular resection may be indicated as a treatment in, for example, advanced stages of oral squamous cell carcinoma (OSCC). Osseous reconstruction of these defects is a fundamental part of static and dynamic masticatory rehabilitation, particularly when dental implants are required. The Segmental Mandibular Defect Reconstruction (SMDR) Registry aims to generate real-world evidence on SMDR through an international, prospective, multicentre case series designed as a registry. While OSCC is a common indication for segmental mandibular resection, the SMDR Registry also aims to capture outcomes for rarer mandibular conditions and the increasing number of collateral damage cases resulting from systemic medication therapies (antiresorptive drugs, immunotherapeutics) or irradiation, which may likewise lead to medication-related osteonecrosis of the mandible (MRONJ) or osteo(radio)necrosis with tumour-like segmental resection of the mandible, highlighting the value of an international database for these less frequent pathologies. Primary objectives are to describe the patient population and current treatment modalities, describe the outcomes and adverse events (AEs) for different treatment modalities, and identify potential predictors for successful autologous reconstruction of SMDs. Approximately 300 patients with a mandibular lesion resulting from bisphosphonate- and immunomodulatory drug-induced osteonecrosis of the mandible, ameloblastoma or osteosarcoma of the mandible, oral metastases related mandibular lesions indicated for segmental resection, or OSCC undergoing SMDR or intending to undergo one- or two-stage reconstruction will be prospectively recruited over a 36-month period. Baseline information, treatment details, and outcome measures will be documented. All treatments will be per the usual practice at participating sites. Outcome measures include clinical, patient-reported, and radiological outcomes; AEs related to the condition and/or treatment with a possible influence on the outcome will be recorded.
- 13 July 2023
- Published by Springer Nature
- p. 463-480
Odontogenic Cysts and Tumors
- 13 July 2023
- Published by Springer Nature
- p. 423-439
Vascular Malformations and Tumors
- 13 July 2023
- Published by Springer Nature
- p. 393-407
Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
- 13 July 2023
- Published by Springer Nature
- p. 393-407
Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
- 13 July 2023
- Published by Springer Nature
- p. 357-379
Head and Neck Lymphoma and Sarcoma
- 13 July 2023
- Published by Springer Nature
- p. 349-356
Salivary Gland Diseases
- 13 July 2023
- Published by Springer Nature
- p. 331-347
Thyroid and Parathyroid Diseases
- 13 July 2023
- Published by Springer Nature
- p. 441-462
Cutaneous and Temporal Bone Malignancies